CJC-1295
What it is & what research shows
Study example availableCJC-1295 is a long-acting growth hormone-releasing hormone analogue studied for sustained GH and IGF-1 stimulation. Placebo-controlled studies in healthy adults aged 21–61 measured GH, IGF-1 and pharmacokinetics after injections under the skin. [1.1]
One selected study: Two randomized, double-blind trials compared long-acting CJC-1295 with placebo, measuring growth hormone, IGF-I and drug-processing characteristics. Healthy adults aged 21–61 were studied for 28 and 49 days. The abstract does not report participant numbers. Across two placebo-controlled healthy-adult trials lasting 28 and 49 days, CJC-1295 was injected subcutaneously as a single dose or on weekly or biweekly multiple-dose schedules. The abstract highlights 30 or 60 microg/kg, but does not link either amount to a specific schedule or list every ascending dose. After a single injection, average growth hormone rose 2- to 10-fold for at least six days and IGF-I rose 1.5- to 3-fold for 9–11 days. After repeated administration, IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported. No author-stated limitations were available in the abstract. The reported endpoints were hormone levels and pharmacokinetics, not demonstrated muscle gain or recovery benefits. [2.1]
Sources & reading scope
- [1.1] Teichman et al., CJC-1295 human studies (2006)Study abstract · healthy adults, subcutaneous administration
- [2.1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Human · Abstract summarized · not a full-paper review
Evidence summarized on PED Evidence
1 completed summaries
1 human-study reports
1 randomized-trial candidates
0 safety-topic reports
Landmark reading
Editorial selections, not an effectiveness ranking or recommendation.
Filter, save and compare CJC-1295 studies →More about CJC-1295: identity, safety & reference details
Also known as CJC1295
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
Placebo-controlled studies in healthy adults aged 21–61 measured GH, IGF-1 and pharmacokinetics after injections under the skin. [1]
- Known half-life
Estimated at 5.8–8.1 days for the long-acting CJC-1295 studied in these human trials. [1]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
The trials measured hormone changes; they did not establish muscle-gain or longevity benefits. The long-acting study value must not be applied to products labeled “no DAC”. [1]
Safety & evidence boundaries
The trials measured hormone changes; they did not establish muscle-gain or longevity benefits. The long-acting study value must not be applied to products labeled “no DAC”.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: CJC-1295 · cjc1295
Searchable names: CJC1295
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Sources for this profile
- 1. Teichman et al., CJC-1295 human studies (2006) Study abstract · healthy adults, subcutaneous administration
Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
CJC-1295 study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.